Generated September 15, 2026 at 8:31 PM ET
· Covers September 15 trading day
· 10 of 199 ready 8-Ks selected
· AI-assisted overview
Today's filings show a mix of corporate actions and clinical updates. SOBR Safe faces Nasdaq delisting after merger failure, and XMAX also faces delisting for discounted share issuances. In M&A, nVent agreed to acquire Maverick Power for $1.75B, while 5E Advanced Materials won a bid for Searles Valley assets. Clinical data was positive for Vera Therapeutics and Summit Therapeutics. Additionally, Hub Group reported preliminary results and a delisting risk, while Curaleaf continued to push its takeover of Aurora.
regulatory
negative
materiality 0.90
September 15, 2026, 3:50 PM ET
SOBR Safe to delist from Nasdaq Sept 16; merger with Clean World Ventures unlikely to close
- Received Nasdaq delisting notice Sept 14; common stock delisted from Nasdaq Capital Market at open Sept 16.
- Will not appeal delisting or equity deficiency; shares to move to OTCQB tier under ticker SOBR upon approval.
- Merger with Clean World Ventures (CWV) won't close by Oct 15 termination date; company cites need for new Nasdaq listing application.
CURLF
Curaleaf Holdings, Inc.
M&A
positive
materiality 0.85
September 15, 2026, 3:56 PM ET
Curaleaf urges Aurora shareholders to tender; touts 45% premium, $4.00 offer
- Offer of 0.3463 Curaleaf shares + $0.75 cash per Aurora share implies $4.00 price, 45% premium to $2.76.
- Combined company would span 17 countries, >$1.5B revenue, ~$350M adj. EBITDA, $40M+ annual synergies.
- Aurora's 4-quarter revenue down 14%, adj. EBITDA down 78%, operating cash flow negative; Curaleaf shares up ~50% vs Aurora down ~34% in H1 2026.
M&A
positive
materiality 0.80
September 15, 2026, 5:10 PM ET
nVent to acquire data center power firm Maverick Power for $1.75B
- nVent (via Hoffman Schroff) to acquire Maverick Power for $1.75B, plus up to $550M earnout based on 2027-2028 performance.
- Maverick Power: data center power distribution, ~900 employees, $527M revenue for 12 months ended June 30, 2026.
- Financing: new notes offering, $600M term loan, $250M revolver, and up to $1.5B bridge; total new debt ~$1.65B.
regulatory
positive
materiality 0.80
September 15, 2026, 4:58 PM ET
FDA clears Beta Bionics Mint patch pump; 3D Intelligence 510(k) submitted
- Mint FDA clearance announced Sept 14, 2026; full U.S. launch expected Q1 2027, ahead of prior target; at least 1.5M disposable units capacity in 2027.
- 510(k) for 3D Intelligence insulin-dosing algorithm submitted; if cleared, powers iLet 3D by end 2026 and Mint 3D at launch.
- Mint launches exclusively via pharmacy channel; ~40% insured U.S. lives at launch, rising to ≥50% within first year.
FEAM
5E Advanced Materials, Inc.
M&A
positive
materiality 1.00
September 15, 2026, 9:00 AM ET
5E Advanced Materials wins bid for Searles Valley Minerals assets: $3.4M cash, 8.3M shares, $6.2M note
- Consideration: ~$3.4M cash (less $300k deposit), 8.3M FEAM shares, ~$6.2M senior unsecured note at 14.5% PIK.
- Assets include Argus, Westend, Trona production facilities, ~9,000 acres Searles Lake brine, Trona Railway, water utilities.
- Conditions: Bankruptcy Court approval, STB authorization for railroad, and $10M bridge facility from Nirma Limited (8% PIK, 270-day maturity).
regulatory
negative
materiality 0.70
September 15, 2026, 4:45 PM ET
XMAX faces potential Nasdaq delisting for unapproved discounted share issuances
- On Sep 10, 2026, Nasdaq notified XMAX of non-compliance with Listing Rule 5635(d) requiring shareholder approval for issuances >20% at below minimum price.
- Dec 19, 2025 issuance of 1,187,500 shares at $4.21 vs NOCP $6.02 (Dec 18) and 5-day avg $5.98.
- Additional discounted issuances: 8.5M shares (Mar 9), 1.958M (Mar 30), 8.55M (Apr 24, 2026) all below minimum price.
earnings
negative
materiality 0.90
September 15, 2026, 6:02 AM ET
Hub Group reports preliminary H1 2026 revenue $1.7-1.8B, expects operating loss; faces Nasdaq delisting
- Preliminary H1 2026 revenue $1.70-1.80B; expects operating loss before one-time charges; fuel, rail, drayage costs up.
- Restatement ongoing; expects Nasdaq Staff Delisting Determination, plans appeal; filings targeted Q4 2026.
- David Yeager appointed Chairman and CEO; Phillip Yeager remains President and Vice Chairman.
VERA
Vera Therapeutics, Inc.
other material
positive
materiality 0.95
September 15, 2026, 6:45 AM ET
TRUTAKNA meets all endpoints in ORIGIN 3 final analysis; stabilizes eGFR, cuts progression risk 76%
- Mean eGFR change at 52 weeks: TRUTAKNA -0.1 vs placebo -5.7 mL/min/1.73m² (treatment effect 5.6, p<0.0001).
- Annualized eGFR slope to 104 weeks: -0.6 vs -5.6 mL/min/1.73m²/yr (effect 5.0, p<0.0001).
- Composite kidney progression events: 11 vs 38; HR 0.24 (95% CI 0.12-0.48), 76% risk reduction (p<0.0001).
SMG
SCOTTS MIRACLE-GRO CO
debt
positive
materiality 0.70
September 15, 2026, 8:33 AM ET
Scotts Miracle-Gro redeems $250M notes, renews AR facility, starts share repurchases
- Redeemed all $250M of 5.250% senior notes due 2026 on Sept 11, using revolver debt and FY2026 excess FCF.
- Renewed $750M accounts receivable facility with JPMorgan Chase, extending maturity to Aug 31, 2027.
- Repurchased $25M of shares in August, initiating the $500M buyback program authorized by the board.
SMMT
Summit Therapeutics Inc.
other material
positive
materiality 0.85
September 15, 2026, 8:44 AM ET
Summit reports consistent OS benefit for ivonescimab in HARMONi; HARMONi-2 OS data positive
- Updated HARMONi OS analysis: global ITT HR 0.76 (95% CI 0.61-0.95; p=0.0151), median OS 16.8 vs 14.0 months.
- Western subgroup OS HR 0.76 (95% CI 0.52-1.10), consistent with global; median follow-up 23.2 months.
- HARMONi-2 (Akeso-sponsored) OS: HR 0.73 (95% CI 0.57-0.95; p=0.009) vs pembrolizumab; median OS 30.8 vs 22.6 months.